Pfizer announces that its RSV vaccine, Abrysvo, could be effective in protecting people aged 18 to 59 against the disease. The company plans to submit the necessary information to the FDA for potential expansion of the vaccine's availability.
An RSV vaccine already used for older adults could help protect people as young as 18 who are at increased risk of the disease, drugmaker Pfizer said in a news release Tuesday. The company said it would submit the information to the U.S. Food and Drug Administration for potential expansion of the vaccine’s availability to people ages 18 to 59. Pfizer ’s RSV vaccine, Abrysvo , was approved for people 60 and older last year.
5% of adults age 18 to 49 and 24.3% of adults 50 to 64 in the U.S. have a chronic condition that puts them at severe risk of the disease.“These encouraging results provide evidence that ABRYSVO can help protect adults with increased risk against RSV-associated illness,” Annaliesa Anderson, a senior vice president at Pfizer and head of the company’s vaccine research and development, said in a news release.
Pfizer RSV Vaccine Abrysvo Younger Adults FDA Clinical Trial Immune Response Neutralizing Antibodies
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Risk for Preterm Birth Stops Maternal RSV Vaccine TrialWith a maternal vaccine already on the market to protect newborns from RSV, the outlook for another looked promising, but latest phase 3 trial of a new candidate is now halted over safety concerns.
Read more »
New Infant RSV Antibody Treatment Shows Strong ResultsThe new RSV antibody treatment for babies has been highly effective in its first season, according to a first look at data from four children’s hospitals.
Read more »
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible usePfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
Read more »
Adding Vaccine to Immunotherapy for Liver Cancer Shows Promise in Early TrialA custom-made anti-tumor vaccine added to standard immunotherapy was twice as likely to shrink liver cancer as when a patient received immunotherapy alone, a new study shows.
Read more »
New Oral Vaccine Shows Promise as Alternative to Antibiotics for Recurring UTIsA new study suggests that an oral vaccine could be a potential alternative to antibiotics for people with recurring urinary tract infections (UTIs). More than half of the patients who received the oral spray vaccine remained infection-free for nine years, with no notable side effects. The vaccine was found to be safe in the long term and resulted in fewer and less severe UTIs.
Read more »
Geneos vaccine shows efficacy in reducing liver tumors in trialGeneos treatment is a DNA vaccine that delivers the genetic code of mutated proteins into cells.
Read more »